05:13 PM EDT, 05/21/2024 (MT Newswires) -- Eupraxia Pharmaceuticals Inc. ( EPRX ) , a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, was up as much as 70% in US after trade Tuesday as it announced additional positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis.

EPRX was at last look up nearer 40% in US after hours.

"New data from the RESOLVE trial's first and second cohorts showed good tolerability and extended signals of potential efficacy out to 24 weeks without meaningful side effects," said Dr. James Helliwell, Chief Executive Officer in a statement. "We're also seeing data from the third cohort of the trial that suggests improvements in patient-reported symptoms and histological outcomes at 12 weeks. Overall, we are seeing a growing volume of positive data, while maintaining a solid safety margin."

The company said it intends to continue to periodically disclose additional data from the trial.